No Data
No Data
Oncternal Participating in Virtual Fireside Chat With Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer
SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced it will
Oncternal Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line
Oncternal Therapeutics Files for Mixed Shelf Offering
Analysts Offer Insights on Healthcare Companies: Joint (JYNT), Xtant Medical Holdings (XTNT) and Oncternal Therapeutics (ONCT)
Q4 2023 Oncternal Therapeutics Inc Earnings Call
Earnings Call Summary | Oncternal Therapeutics(ONCT.US) Q4 2023 Earnings Conference
The following is a summary of the Oncternal Therapeutics, Inc. (ONCT) Q4 2023 Earnings Call Transcript:Financial Performance:Oncternal Therapeutics' Q4 2023 revenue came from grants that totaled $0.3
No Data